Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This study aimed to evaluate the safety and feasibility of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), for elderly patients (aged 75 years and older) with resectable and borderline resectable pancreatic ductal adenocarcinoma (R/BR-PDAC). A post hoc analysis was conducted using data from a randomized controlled trial on NAC for R/BR-PDAC (CSGO-HBP-015). Patients were divided into two groups: those aged 75 years and older (7/46 in GS and 16/48 in GA) and those under 75 years. Short-term outcomes, including resection rates, adverse events (AEs), postoperative complications, and the administration of adjuvant chemotherapy, were compared between age groups for both regimens. The incidence of AEs in patients aged 75 years and older tended to be higher than those of younger patients in both chemotherapy arms, but the differences were not statistically significant. However, the resection rates, postoperative complication rates, and the administration of adjuvant chemotherapy were not affected by age. Both regimens showed comparable safety profiles in elderly and younger cohorts. The GA and GS regimens can be safely administered as NAC for R/BR-PDAC in elderly patients without adversely affecting postoperative outcomes. These findings suggest that both regimens are feasible NAC options even for patients 75 years and older, supporting the need for further randomized controlled trials to validate these outcomes in the elderly population.Trial registration. UMIN Clinical Trials Registry UMIN000021484. This trial began in April 2016, and first registration (First Posted date) is 01/04/2016.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma
- Date Crossref
- 12/11/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Osaka pays non établi dans la noticeUniversité ou école supérieure
-
Osaka International Cancer Institute Department of Gastroenterological Surgery pays non établi dans la noticeStructure de recherche
-
Toyonaka Municipal Hospital Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
-
Osaka City General Hospital pays non établi dans la noticeÉtablissement de santé
-
Rinku General Medical Center Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
-
Hyogo Prefectural Nishinomiya Hospital Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
-
Osaka Rosai Hospital Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
-
Osaka Police Hospital Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
-
Kansai Rosai Hospital Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
-
Osaka Hospital Department of Surgery pays non établi dans la noticeÉtablissement de santé
-
Osaka Prefectural Medical Center pays non établi dans la noticeÉtablissement de santé
-
Graduate School of Medicine Department of Gastroenterological Surgery pays non établi dans la noticeUniversité ou école supérieure
The University of Osaka, Department of Gastroenterological Surgery — Osaka International Cancer Institute et Department of Gastroenterological Surgery — Toyonaka Municipal Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.